Fig. 2: Course of cancer-specific health-related quality of life (EORTC QLQ-C30 functional scales and global health status) over time in patients treated with radium-223 for metastatic castration-resistant prostate cancer.
Bars indicate mean scores with 95% confidence intervals.
